Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Results of Operations and Financial Condition
|Press release dated February 27, 2019.|
Intra-Cellular Therapies, Inc. Exhibit
EX-99.1 2 d710120dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE NEW YORK,…
To view the full exhibit click
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.